LOTRISONE
LOE ApproachingNDATOPICALLOTION
Approved
Dec 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOTRISONE is a topical lotion combining an antifungal and corticosteroid approved by Merck & Co. in December 2000. The fixed-dose combination treats fungal skin infections with inflammatory components. It is applied directly to affected skin areas.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100) signals potential team contraction or strategic repositioning efforts.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LOTRISONE currently has zero linked job openings, reflecting its mature LOE-approaching status and limited expansion potential. Career opportunities are primarily in defensive commercial roles focused on market protection and transition planning rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on LOTRISONE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.